These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7103612)

  • 1. Some observations on the effects of enantiomers of two benzomorphan narcotic antagonists and atropine on analgesia, tremor and hypothermia produced by oxotremorine.
    Ben-Sreti MM; Sewell RD; Upton N
    Arch Int Pharmacodyn Ther; 1982 Apr; 256(2):219-27. PubMed ID: 7103612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereospecific inhibition of oxotremorine-induced antinociception by (+)-isomers of opioid antagonists: comparison with opioid receptor agonists.
    Ben-Sreti MM; Sewell RD
    J Pharm Pharmacol; 1982 Aug; 34(8):501-5. PubMed ID: 6126560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinergic involvement in the modulation of oxotremorine-tremor in mice by propranolol.
    Alkondon M; Ray A; Sen P
    Arch Int Pharmacodyn Ther; 1985 Sep; 277(1):161-7. PubMed ID: 2865935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of oxotremorine tremor and hypothermia by injections of drugs into the cerebral ventricles of the mouse.
    Doggett NS; O'Farrell SA
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):149-55. PubMed ID: 1012335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tremorine-oxotremorine-induced tremor, hypothermia and analgesia, and physostigmine toxicity, in mice after pretreatment with beta-adrenoceptor antagonists.
    Barar FS; Madan BR
    J Pharm Pharmacol; 1976 Apr; 28(4):286-9. PubMed ID: 6716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of naloxone and Mr 2266 on thermonociceptive reactions in diabetic mice.
    Ramabadran K; Bansinath M; Turndorf H; Puig MM
    NIDA Res Monogr; 1989; 95():528-9. PubMed ID: 2561849
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional reactivity of central cholinergic systems following desipramine treatments and sleep deprivation.
    Murugaiah KD; Ukponmwan OE
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Oct; 368(4):294-300. PubMed ID: 13680087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscarinic actions and receptor binding of the enantiomers of BM 130, an alkylating analog of oxotremorine.
    Ringdahl B; Katz ED; Roch M; Jenden DJ
    J Pharmacol Exp Ther; 1989 Apr; 249(1):210-5. PubMed ID: 2709331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonmuscarinic neurotoxicity of oxotremorine.
    Witkin JM; Alvarado-Garcia R; Lee MA; Witkin KM
    J Pharmacol Exp Ther; 1987 Apr; 241(1):34-41. PubMed ID: 3572794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine and oxotremorine hypothermia in the pigeon: dopaminergic-cholinergic interaction and the effect of paleostriatal lesions.
    Pyörnilä A
    Med Biol; 1980 Apr; 58(2):87-93. PubMed ID: 7432010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscarinic actions of an N-methyl-N-2-bromoethylamino analog of oxotremorine (BR 401) in the mouse.
    Ringdahl B; Jenden DJ
    J Pharmacol Exp Ther; 1987 Feb; 240(2):370-5. PubMed ID: 3806401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of bremazocine on locomotor activity in DBA/2 and C57BL/6 mice.
    Castellano C; Pavone F
    Arch Int Pharmacodyn Ther; 1985 Nov; 278(1):45-52. PubMed ID: 4096608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacology of N-carbamoyl-2-(2,6-dichlorophenyl)acetamidine hydrochloride (LON-954) a new tremorogenic agent.
    Coward DM; Doggett NS; Sayers AC
    Arzneimittelforschung; 1977; 27(12):2326-32. PubMed ID: 580044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the benzomorphan kappa-opiate, MR 2266 and its (+) enantiomer MR 2267, on thermonociceptive reactions in different strains of mice.
    Bansinath M; Ramabadran K; Turndorf H; Puig MM
    Neurosci Lett; 1990 Sep; 117(1-2):212-7. PubMed ID: 1963214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
    Baker AK; Meert TF
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of the analgesic activity of narcotic antagonists by a modified hot-plate procedure.
    O'Callaghan JP; Holtzman SG
    J Pharmacol Exp Ther; 1975 Mar; 192(3):497-505. PubMed ID: 1168252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperalgesia produced by intrathecal opioid antagonists depends on receptor selectivity and noxious stimulus.
    Pilcher CW; Browne JL
    NIDA Res Monogr; 1986; 75():469-72. PubMed ID: 2828994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereospecific effects of a kappa-opiate antagonist on the actions of morphine in morphine-tolerant rats.
    Bhargava HN; Kremer EK; Gibbons MO; Philips BJ; Driver JW; Chou M
    Eur J Pharmacol; 1989 Dec; 173(2-3):159-64. PubMed ID: 2560431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional differences in receptor reserve for analogs of oxotremorine in vivo: implications for development of selective muscarinic agonists.
    Ringdahl B; Roch M; Jenden DJ
    J Pharmacol Exp Ther; 1987 Aug; 242(2):464-71. PubMed ID: 3612545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on novel morphine antagonists in the animal experiment (author's transl)].
    Kuhn FJ; Stockhaus K
    Arzneimittelforschung; 1976; 26(11):2009-14. PubMed ID: 1037235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.